Genomic Health, Inc. (NASDAQ:GHDX) Insider Sells $256,905.00 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 4,500 shares of Genomic Health stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $57.09, for a total value of $256,905.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

James J. Vaughn also recently made the following trade(s):

  • On Thursday, June 6th, James J. Vaughn sold 8,745 shares of Genomic Health stock. The stock was sold at an average price of $52.47, for a total value of $458,850.15.

Shares of NASDAQ:GHDX opened at $56.20 on Friday. The company has a market capitalization of $2.14 billion, a PE ratio of 53.52 and a beta of 1.07. Genomic Health, Inc. has a 1 year low of $50.77 and a 1 year high of $92.18. The stock has a fifty day simple moving average of $54.75. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.67 and a quick ratio of 5.67.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.05. The firm had revenue of $108.80 million during the quarter, compared to analysts’ expectations of $106.75 million. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. Genomic Health’s revenue for the quarter was up 17.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) earnings per share. On average, equities analysts anticipate that Genomic Health, Inc. will post 1.46 earnings per share for the current year.

GHDX has been the subject of a number of research reports. Piper Jaffray Companies reiterated a “buy” rating on shares of Beigene in a research note on Thursday, June 20th. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 4th. Deutsche Bank set a $18.00 price target on shares of Commercial Metals and gave the stock a “buy” rating in a research note on Thursday, May 30th. Zacks Investment Research downgraded shares of Guaranty Federal Bancshares from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Finally, ValuEngine downgraded shares of Valero Energy from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $64.86.

Large investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in Genomic Health by 166.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock worth $55,000 after purchasing an additional 493 shares in the last quarter. Manchester Capital Management LLC bought a new stake in Genomic Health in the first quarter worth $56,000. Pearl River Capital LLC bought a new stake in Genomic Health in the first quarter worth $70,000. Royce & Associates LP boosted its holdings in Genomic Health by 22.8% in the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after purchasing an additional 273 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in Genomic Health by 34.9% in the fourth quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after purchasing an additional 516 shares in the last quarter. Hedge funds and other institutional investors own 95.54% of the company’s stock.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Read More: Why are percentage decliners important?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.